

Global Diagnostic Nuclear Medicines Market Growth 2025-2031

<https://marketpublishers.com/r/G182C109BD4EN.html>

Date: December 2025

Pages: 107

Price: US\$ 3,660.00 (Single User License)

ID: G182C109BD4EN

Abstracts

The global Diagnostic Nuclear Medicines market size is predicted to grow from US\$ 5572 million in 2025 to US\$ 8436 million in 2031; it is expected to grow at a CAGR of 7.2% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Diagnostic radiopharmaceuticals. Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis

The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the

increasing demand for effective and safe diagnostic imaging solutions.

LP Information, Inc. (LPI) ' newest research report, the “Diagnostic Nuclear Medicines Industry Forecast” looks at past sales and reviews total world Diagnostic Nuclear Medicines sales in 2024, providing a comprehensive analysis by region and market sector of projected Diagnostic Nuclear Medicines sales for 2025 through 2031. With Diagnostic Nuclear Medicines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Diagnostic Nuclear Medicines industry.

This Insight Report provides a comprehensive analysis of the global Diagnostic Nuclear Medicines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diagnostic Nuclear Medicines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Diagnostic Nuclear Medicines market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diagnostic Nuclear Medicines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diagnostic Nuclear Medicines.

This report presents a comprehensive overview, market shares, and growth opportunities of Diagnostic Nuclear Medicines market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Tc-99m

F-18

Other

Segmentation by Application:

Oncology

Cardiology

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Cardinal Health

GE Healthcare

Curium Pharma

Jubilant Pharma

Bracco Imaging

Novartis

SIEMENS

China Isotope & Radiation

Dongcheng

Lantheus

Eli Lilly

Key Questions Addressed in this Report

What is the 10-year outlook for the global Diagnostic Nuclear Medicines market?

What factors are driving Diagnostic Nuclear Medicines market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Diagnostic Nuclear Medicines market opportunities vary by end market size?

How does Diagnostic Nuclear Medicines break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Diagnostic Nuclear Medicines Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for Diagnostic Nuclear Medicines by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for Diagnostic Nuclear Medicines by Country/Region, 2020, 2024 & 2031
- 2.2 Diagnostic Nuclear Medicines Segment by Type
 - 2.2.1 Tc-99m
 - 2.2.2 F-18
 - 2.2.3 Other
- 2.3 Diagnostic Nuclear Medicines Sales by Type
 - 2.3.1 Global Diagnostic Nuclear Medicines Sales Market Share by Type (2020-2025)
 - 2.3.2 Global Diagnostic Nuclear Medicines Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global Diagnostic Nuclear Medicines Sale Price by Type (2020-2025)
- 2.4 Diagnostic Nuclear Medicines Segment by Application
 - 2.4.1 Oncology
 - 2.4.2 Cardiology
 - 2.4.3 Other
- 2.5 Diagnostic Nuclear Medicines Sales by Application
 - 2.5.1 Global Diagnostic Nuclear Medicines Sale Market Share by Application (2020-2025)
 - 2.5.2 Global Diagnostic Nuclear Medicines Revenue and Market Share by Application (2020-2025)

2.5.3 Global Diagnostic Nuclear Medicines Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Diagnostic Nuclear Medicines Breakdown Data by Company

3.1.1 Global Diagnostic Nuclear Medicines Annual Sales by Company (2020-2025)

3.1.2 Global Diagnostic Nuclear Medicines Sales Market Share by Company (2020-2025)

3.2 Global Diagnostic Nuclear Medicines Annual Revenue by Company (2020-2025)

3.2.1 Global Diagnostic Nuclear Medicines Revenue by Company (2020-2025)

3.2.2 Global Diagnostic Nuclear Medicines Revenue Market Share by Company (2020-2025)

3.3 Global Diagnostic Nuclear Medicines Sale Price by Company

3.4 Key Manufacturers Diagnostic Nuclear Medicines Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Diagnostic Nuclear Medicines Product Location Distribution

3.4.2 Players Diagnostic Nuclear Medicines Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR DIAGNOSTIC NUCLEAR MEDICINES BY GEOGRAPHIC REGION

4.1 World Historic Diagnostic Nuclear Medicines Market Size by Geographic Region (2020-2025)

4.1.1 Global Diagnostic Nuclear Medicines Annual Sales by Geographic Region (2020-2025)

4.1.2 Global Diagnostic Nuclear Medicines Annual Revenue by Geographic Region (2020-2025)

4.2 World Historic Diagnostic Nuclear Medicines Market Size by Country/Region (2020-2025)

4.2.1 Global Diagnostic Nuclear Medicines Annual Sales by Country/Region (2020-2025)

4.2.2 Global Diagnostic Nuclear Medicines Annual Revenue by Country/Region (2020-2025)

4.3 Americas Diagnostic Nuclear Medicines Sales Growth

- 4.4 APAC Diagnostic Nuclear Medicines Sales Growth
- 4.5 Europe Diagnostic Nuclear Medicines Sales Growth
- 4.6 Middle East & Africa Diagnostic Nuclear Medicines Sales Growth

5 AMERICAS

- 5.1 Americas Diagnostic Nuclear Medicines Sales by Country
 - 5.1.1 Americas Diagnostic Nuclear Medicines Sales by Country (2020-2025)
 - 5.1.2 Americas Diagnostic Nuclear Medicines Revenue by Country (2020-2025)
- 5.2 Americas Diagnostic Nuclear Medicines Sales by Type (2020-2025)
- 5.3 Americas Diagnostic Nuclear Medicines Sales by Application (2020-2025)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Diagnostic Nuclear Medicines Sales by Region
 - 6.1.1 APAC Diagnostic Nuclear Medicines Sales by Region (2020-2025)
 - 6.1.2 APAC Diagnostic Nuclear Medicines Revenue by Region (2020-2025)
- 6.2 APAC Diagnostic Nuclear Medicines Sales by Type (2020-2025)
- 6.3 APAC Diagnostic Nuclear Medicines Sales by Application (2020-2025)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Diagnostic Nuclear Medicines by Country
 - 7.1.1 Europe Diagnostic Nuclear Medicines Sales by Country (2020-2025)
 - 7.1.2 Europe Diagnostic Nuclear Medicines Revenue by Country (2020-2025)
- 7.2 Europe Diagnostic Nuclear Medicines Sales by Type (2020-2025)
- 7.3 Europe Diagnostic Nuclear Medicines Sales by Application (2020-2025)
- 7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Diagnostic Nuclear Medicines by Country

8.1.1 Middle East & Africa Diagnostic Nuclear Medicines Sales by Country
(2020-2025)

8.1.2 Middle East & Africa Diagnostic Nuclear Medicines Revenue by Country
(2020-2025)

8.2 Middle East & Africa Diagnostic Nuclear Medicines Sales by Type (2020-2025)

8.3 Middle East & Africa Diagnostic Nuclear Medicines Sales by Application
(2020-2025)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Diagnostic Nuclear Medicines

10.3 Manufacturing Process Analysis of Diagnostic Nuclear Medicines

10.4 Industry Chain Structure of Diagnostic Nuclear Medicines

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Diagnostic Nuclear Medicines Distributors

11.3 Diagnostic Nuclear Medicines Customer

12 WORLD FORECAST REVIEW FOR DIAGNOSTIC NUCLEAR MEDICINES BY GEOGRAPHIC REGION

12.1 Global Diagnostic Nuclear Medicines Market Size Forecast by Region

12.1.1 Global Diagnostic Nuclear Medicines Forecast by Region (2026-2031)

12.1.2 Global Diagnostic Nuclear Medicines Annual Revenue Forecast by Region (2026-2031)

12.2 Americas Forecast by Country (2026-2031)

12.3 APAC Forecast by Region (2026-2031)

12.4 Europe Forecast by Country (2026-2031)

12.5 Middle East & Africa Forecast by Country (2026-2031)

12.6 Global Diagnostic Nuclear Medicines Forecast by Type (2026-2031)

12.7 Global Diagnostic Nuclear Medicines Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Cardinal Health

13.1.1 Cardinal Health Company Information

13.1.2 Cardinal Health Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.1.3 Cardinal Health Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)

13.1.4 Cardinal Health Main Business Overview

13.1.5 Cardinal Health Latest Developments

13.2 GE Healthcare

13.2.1 GE Healthcare Company Information

13.2.2 GE Healthcare Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.2.3 GE Healthcare Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)

13.2.4 GE Healthcare Main Business Overview

13.2.5 GE Healthcare Latest Developments

13.3 Curium Pharma

13.3.1 Curium Pharma Company Information

13.3.2 Curium Pharma Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.3.3 Curium Pharma Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)

13.3.4 Curium Pharma Main Business Overview

13.3.5 Curium Pharma Latest Developments

13.4 Jubilant Pharma

13.4.1 Jubilant Pharma Company Information

13.4.2 Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.4.3 Jubilant Pharma Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)

13.4.4 Jubilant Pharma Main Business Overview

13.4.5 Jubilant Pharma Latest Developments

13.5 Bracco Imaging

13.5.1 Bracco Imaging Company Information

13.5.2 Bracco Imaging Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.5.3 Bracco Imaging Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)

13.5.4 Bracco Imaging Main Business Overview

13.5.5 Bracco Imaging Latest Developments

13.6 Novartis

13.6.1 Novartis Company Information

13.6.2 Novartis Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.6.3 Novartis Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)

13.6.4 Novartis Main Business Overview

13.6.5 Novartis Latest Developments

13.7 SIEMENS

13.7.1 SIEMENS Company Information

13.7.2 SIEMENS Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.7.3 SIEMENS Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)

13.7.4 SIEMENS Main Business Overview

13.7.5 SIEMENS Latest Developments

13.8 China Isotope & Radiation

13.8.1 China Isotope & Radiation Company Information

13.8.2 China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.8.3 China Isotope & Radiation Diagnostic Nuclear Medicines Sales, Revenue, Price

and Gross Margin (2020-2025)

13.8.4 China Isotope & Radiation Main Business Overview

13.8.5 China Isotope & Radiation Latest Developments

13.9 Dongcheng

13.9.1 Dongcheng Company Information

13.9.2 Dongcheng Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.9.3 Dongcheng Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross

Margin (2020-2025)

13.9.4 Dongcheng Main Business Overview

13.9.5 Dongcheng Latest Developments

13.10 Lantheus

13.10.1 Lantheus Company Information

13.10.2 Lantheus Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.10.3 Lantheus Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross

Margin (2020-2025)

13.10.4 Lantheus Main Business Overview

13.10.5 Lantheus Latest Developments

13.11 Eli Lilly

13.11.1 Eli Lilly Company Information

13.11.2 Eli Lilly Diagnostic Nuclear Medicines Product Portfolios and Specifications

13.11.3 Eli Lilly Diagnostic Nuclear Medicines Sales, Revenue, Price and Gross

Margin (2020-2025)

13.11.4 Eli Lilly Main Business Overview

13.11.5 Eli Lilly Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Diagnostic Nuclear Medicines Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Diagnostic Nuclear Medicines Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of Tc-99m

Table 4. Major Players of F-18

Table 5. Major Players of Other

Table 6. Global Diagnostic Nuclear Medicines Sales by Type (2020-2025) & (K Units)

Table 7. Global Diagnostic Nuclear Medicines Sales Market Share by Type (2020-2025)

Table 8. Global Diagnostic Nuclear Medicines Revenue by Type (2020-2025) & (\$ million)

Table 9. Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2020-2025)

Table 10. Global Diagnostic Nuclear Medicines Sale Price by Type (2020-2025) & (USD/Unit)

Table 11. Global Diagnostic Nuclear Medicines Sale by Application (2020-2025) & (K Units)

Table 12. Global Diagnostic Nuclear Medicines Sale Market Share by Application (2020-2025)

Table 13. Global Diagnostic Nuclear Medicines Revenue by Application (2020-2025) & (\$ million)

Table 14. Global Diagnostic Nuclear Medicines Revenue Market Share by Application (2020-2025)

Table 15. Global Diagnostic Nuclear Medicines Sale Price by Application (2020-2025) & (USD/Unit)

Table 16. Global Diagnostic Nuclear Medicines Sales by Company (2020-2025) & (K Units)

Table 17. Global Diagnostic Nuclear Medicines Sales Market Share by Company (2020-2025)

Table 18. Global Diagnostic Nuclear Medicines Revenue by Company (2020-2025) & (\$ millions)

Table 19. Global Diagnostic Nuclear Medicines Revenue Market Share by Company (2020-2025)

Table 20. Global Diagnostic Nuclear Medicines Sale Price by Company (2020-2025) & (USD/Unit)

Table 21. Key Manufacturers Diagnostic Nuclear Medicines Producing Area Distribution and Sales Area

Table 22. Players Diagnostic Nuclear Medicines Products Offered

Table 23. Diagnostic Nuclear Medicines Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Diagnostic Nuclear Medicines Sales by Geographic Region (2020-2025) & (K Units)

Table 27. Global Diagnostic Nuclear Medicines Sales Market Share Geographic Region (2020-2025)

Table 28. Global Diagnostic Nuclear Medicines Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 29. Global Diagnostic Nuclear Medicines Revenue Market Share by Geographic Region (2020-2025)

Table 30. Global Diagnostic Nuclear Medicines Sales by Country/Region (2020-2025) & (K Units)

Table 31. Global Diagnostic Nuclear Medicines Sales Market Share by Country/Region (2020-2025)

Table 32. Global Diagnostic Nuclear Medicines Revenue by Country/Region (2020-2025) & (\$ millions)

Table 33. Global Diagnostic Nuclear Medicines Revenue Market Share by Country/Region (2020-2025)

Table 34. Americas Diagnostic Nuclear Medicines Sales by Country (2020-2025) & (K Units)

Table 35. Americas Diagnostic Nuclear Medicines Sales Market Share by Country (2020-2025)

Table 36. Americas Diagnostic Nuclear Medicines Revenue by Country (2020-2025) & (\$ millions)

Table 37. Americas Diagnostic Nuclear Medicines Sales by Type (2020-2025) & (K Units)

Table 38. Americas Diagnostic Nuclear Medicines Sales by Application (2020-2025) & (K Units)

Table 39. APAC Diagnostic Nuclear Medicines Sales by Region (2020-2025) & (K Units)

Table 40. APAC Diagnostic Nuclear Medicines Sales Market Share by Region (2020-2025)

Table 41. APAC Diagnostic Nuclear Medicines Revenue by Region (2020-2025) & (\$ millions)

Table 42. APAC Diagnostic Nuclear Medicines Sales by Type (2020-2025) & (K Units)

Table 43. APAC Diagnostic Nuclear Medicines Sales by Application (2020-2025) & (K Units)

Table 44. Europe Diagnostic Nuclear Medicines Sales by Country (2020-2025) & (K Units)

Table 45. Europe Diagnostic Nuclear Medicines Revenue by Country (2020-2025) & (\$ millions)

Table 46. Europe Diagnostic Nuclear Medicines Sales by Type (2020-2025) & (K Units)

Table 47. Europe Diagnostic Nuclear Medicines Sales by Application (2020-2025) & (K Units)

Table 48. Middle East & Africa Diagnostic Nuclear Medicines Sales by Country (2020-2025) & (K Units)

Table 49. Middle East & Africa Diagnostic Nuclear Medicines Revenue Market Share by Country (2020-2025)

Table 50. Middle East & Africa Diagnostic Nuclear Medicines Sales by Type (2020-2025) & (K Units)

Table 51. Middle East & Africa Diagnostic Nuclear Medicines Sales by Application (2020-2025) & (K Units)

Table 52. Key Market Drivers & Growth Opportunities of Diagnostic Nuclear Medicines

Table 53. Key Market Challenges & Risks of Diagnostic Nuclear Medicines

Table 54. Key Industry Trends of Diagnostic Nuclear Medicines

Table 55. Diagnostic Nuclear Medicines Raw Material

Table 56. Key Suppliers of Raw Materials

Table 57. Diagnostic Nuclear Medicines Distributors List

Table 58. Diagnostic Nuclear Medicines Customer List

Table 59. Global Diagnostic Nuclear Medicines Sales Forecast by Region (2026-2031) & (K Units)

Table 60. Global Diagnostic Nuclear Medicines Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 61. Americas Diagnostic Nuclear Medicines Sales Forecast by Country (2026-2031) & (K Units)

Table 62. Americas Diagnostic Nuclear Medicines Annual Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 63. APAC Diagnostic Nuclear Medicines Sales Forecast by Region (2026-2031) & (K Units)

Table 64. APAC Diagnostic Nuclear Medicines Annual Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 65. Europe Diagnostic Nuclear Medicines Sales Forecast by Country (2026-2031) & (K Units)

Table 66. Europe Diagnostic Nuclear Medicines Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 67. Middle East & Africa Diagnostic Nuclear Medicines Sales Forecast by Country (2026-2031) & (K Units)

Table 68. Middle East & Africa Diagnostic Nuclear Medicines Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 69. Global Diagnostic Nuclear Medicines Sales Forecast by Type (2026-2031) & (K Units)

Table 70. Global Diagnostic Nuclear Medicines Revenue Forecast by Type (2026-2031) & (\$ millions)

Table 71. Global Diagnostic Nuclear Medicines Sales Forecast by Application (2026-2031) & (K Units)

Table 72. Global Diagnostic Nuclear Medicines Revenue Forecast by Application (2026-2031) & (\$ millions)

Table 73. Cardinal Health Basic Information, Diagnostic Nuclear Medicines Manufacturing Base, Sales Area and Its Competitors

Table 74. Cardinal Health Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 75. Cardinal Health Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 76. Cardinal Health Main Business

Table 77. Cardinal Health Latest Developments

Table 78. GE Healthcare Basic Information, Diagnostic Nuclear Medicines Manufacturing Base, Sales Area and Its Competitors

Table 79. GE Healthcare Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 80. GE Healthcare Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 81. GE Healthcare Main Business

Table 82. GE Healthcare Latest Developments

Table 83. Curium Pharma Basic Information, Diagnostic Nuclear Medicines Manufacturing Base, Sales Area and Its Competitors

Table 84. Curium Pharma Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 85. Curium Pharma Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 86. Curium Pharma Main Business

Table 87. Curium Pharma Latest Developments

Table 88. Jubilant Pharma Basic Information, Diagnostic Nuclear Medicines

Manufacturing Base, Sales Area and Its Competitors

Table 89. Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 90. Jubilant Pharma Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 91. Jubilant Pharma Main Business

Table 92. Jubilant Pharma Latest Developments

Table 93. Bracco Imaging Basic Information, Diagnostic Nuclear Medicines Manufacturing Base, Sales Area and Its Competitors

Table 94. Bracco Imaging Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 95. Bracco Imaging Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 96. Bracco Imaging Main Business

Table 97. Bracco Imaging Latest Developments

Table 98. Novartis Basic Information, Diagnostic Nuclear Medicines Manufacturing Base, Sales Area and Its Competitors

Table 99. Novartis Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 100. Novartis Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 101. Novartis Main Business

Table 102. Novartis Latest Developments

Table 103. SIEMENS Basic Information, Diagnostic Nuclear Medicines Manufacturing Base, Sales Area and Its Competitors

Table 104. SIEMENS Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 105. SIEMENS Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 106. SIEMENS Main Business

Table 107. SIEMENS Latest Developments

Table 108. China Isotope & Radiation Basic Information, Diagnostic Nuclear Medicines Manufacturing Base, Sales Area and Its Competitors

Table 109. China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 110. China Isotope & Radiation Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 111. China Isotope & Radiation Main Business

Table 112. China Isotope & Radiation Latest Developments

Table 113. Dongcheng Basic Information, Diagnostic Nuclear Medicines Manufacturing

Base, Sales Area and Its Competitors

Table 114. Dongcheng Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 115. Dongcheng Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 116. Dongcheng Main Business

Table 117. Dongcheng Latest Developments

Table 118. Lantheus Basic Information, Diagnostic Nuclear Medicines Manufacturing Base, Sales Area and Its Competitors

Table 119. Lantheus Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 120. Lantheus Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 121. Lantheus Main Business

Table 122. Lantheus Latest Developments

Table 123. Eli Lilly Basic Information, Diagnostic Nuclear Medicines Manufacturing Base, Sales Area and Its Competitors

Table 124. Eli Lilly Diagnostic Nuclear Medicines Product Portfolios and Specifications

Table 125. Eli Lilly Diagnostic Nuclear Medicines Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 126. Eli Lilly Main Business

Table 127. Eli Lilly Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Diagnostic Nuclear Medicines

Figure 2. Diagnostic Nuclear Medicines Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Diagnostic Nuclear Medicines Sales Growth Rate 2020-2031 (K Units)

Figure 7. Global Diagnostic Nuclear Medicines Revenue Growth Rate 2020-2031 (\$ millions)

Figure 8. Diagnostic Nuclear Medicines Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Figure 9. Diagnostic Nuclear Medicines Sales Market Share by Country/Region (2024)

Figure 10. Diagnostic Nuclear Medicines Sales Market Share by Country/Region (2020, 2024 & 2031)

Figure 11. Product Picture of Tc-99m

Figure 12. Product Picture of F-18

Figure 13. Product Picture of Other

Figure 14. Global Diagnostic Nuclear Medicines Sales Market Share by Type in 2025

Figure 15. Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2020-2025)

Figure 16. Diagnostic Nuclear Medicines Consumed in Oncology

Figure 17. Global Diagnostic Nuclear Medicines Market: Oncology (2020-2025) & (K Units)

Figure 18. Diagnostic Nuclear Medicines Consumed in Cardiology

Figure 19. Global Diagnostic Nuclear Medicines Market: Cardiology (2020-2025) & (K Units)

Figure 20. Diagnostic Nuclear Medicines Consumed in Other

Figure 21. Global Diagnostic Nuclear Medicines Market: Other (2020-2025) & (K Units)

Figure 22. Global Diagnostic Nuclear Medicines Sale Market Share by Application (2024)

Figure 23. Global Diagnostic Nuclear Medicines Revenue Market Share by Application in 2025

Figure 24. Diagnostic Nuclear Medicines Sales by Company in 2025 (K Units)

Figure 25. Global Diagnostic Nuclear Medicines Sales Market Share by Company in 2025

Figure 26. Diagnostic Nuclear Medicines Revenue by Company in 2025 (\$ millions)

Figure 27. Global Diagnostic Nuclear Medicines Revenue Market Share by Company in 2025

Figure 28. Global Diagnostic Nuclear Medicines Sales Market Share by Geographic Region (2020-2025)

Figure 29. Global Diagnostic Nuclear Medicines Revenue Market Share by Geographic Region in 2025

Figure 30. Americas Diagnostic Nuclear Medicines Sales 2020-2025 (K Units)

Figure 31. Americas Diagnostic Nuclear Medicines Revenue 2020-2025 (\$ millions)

Figure 32. APAC Diagnostic Nuclear Medicines Sales 2020-2025 (K Units)

Figure 33. APAC Diagnostic Nuclear Medicines Revenue 2020-2025 (\$ millions)

Figure 34. Europe Diagnostic Nuclear Medicines Sales 2020-2025 (K Units)

Figure 35. Europe Diagnostic Nuclear Medicines Revenue 2020-2025 (\$ millions)

Figure 36. Middle East & Africa Diagnostic Nuclear Medicines Sales 2020-2025 (K Units)

Figure 37. Middle East & Africa Diagnostic Nuclear Medicines Revenue 2020-2025 (\$ millions)

Figure 38. Americas Diagnostic Nuclear Medicines Sales Market Share by Country in 2025

Figure 39. Americas Diagnostic Nuclear Medicines Revenue Market Share by Country (2020-2025)

Figure 40. Americas Diagnostic Nuclear Medicines Sales Market Share by Type (2020-2025)

Figure 41. Americas Diagnostic Nuclear Medicines Sales Market Share by Application (2020-2025)

Figure 42. United States Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 43. Canada Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 44. Mexico Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 45. Brazil Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 46. APAC Diagnostic Nuclear Medicines Sales Market Share by Region in 2025

Figure 47. APAC Diagnostic Nuclear Medicines Revenue Market Share by Region (2020-2025)

Figure 48. APAC Diagnostic Nuclear Medicines Sales Market Share by Type (2020-2025)

Figure 49. APAC Diagnostic Nuclear Medicines Sales Market Share by Application (2020-2025)

Figure 50. China Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 51. Japan Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 52. South Korea Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 53. Southeast Asia Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 54. India Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 55. Australia Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 56. China Taiwan Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 57. Europe Diagnostic Nuclear Medicines Sales Market Share by Country in 2025

Figure 58. Europe Diagnostic Nuclear Medicines Revenue Market Share by Country (2020-2025)

Figure 59. Europe Diagnostic Nuclear Medicines Sales Market Share by Type (2020-2025)

Figure 60. Europe Diagnostic Nuclear Medicines Sales Market Share by Application (2020-2025)

Figure 61. Germany Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 62. France Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 63. UK Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 64. Italy Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 65. Russia Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 66. Middle East & Africa Diagnostic Nuclear Medicines Sales Market Share by Country (2020-2025)

Figure 67. Middle East & Africa Diagnostic Nuclear Medicines Sales Market Share by Type (2020-2025)

Figure 68. Middle East & Africa Diagnostic Nuclear Medicines Sales Market Share by Application (2020-2025)

Figure 69. Egypt Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 70. South Africa Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 71. Israel Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 72. Turkey Diagnostic Nuclear Medicines Revenue Growth 2020-2025 (\$ millions)

Figure 73. GCC Countries Diagnostic Nuclear Medicines Revenue Growth 2020-2025

(\$ millions)

Figure 74. Manufacturing Cost Structure Analysis of Diagnostic Nuclear Medicines in 2025

Figure 75. Manufacturing Process Analysis of Diagnostic Nuclear Medicines

Figure 76. Industry Chain Structure of Diagnostic Nuclear Medicines

Figure 77. Channels of Distribution

Figure 78. Global Diagnostic Nuclear Medicines Sales Market Forecast by Region (2026-2031)

Figure 79. Global Diagnostic Nuclear Medicines Revenue Market Share Forecast by Region (2026-2031)

Figure 80. Global Diagnostic Nuclear Medicines Sales Market Share Forecast by Type (2026-2031)

Figure 81. Global Diagnostic Nuclear Medicines Revenue Market Share Forecast by Type (2026-2031)

Figure 82. Global Diagnostic Nuclear Medicines Sales Market Share Forecast by Application (2026-2031)

Figure 83. Global Diagnostic Nuclear Medicines Revenue Market Share Forecast by Application (2026-2031)

I would like to order

Product name: Global Diagnostic Nuclear Medicines Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G182C109BD4EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G182C109BD4EN.html>